Tackling cisplatin resistance in ovarian cancer: what can we do?
作者信息
Perego Paola
机构信息
Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy.
出版信息
Cancer Drug Resist. 2021 Jul 8;4(4):755-757. doi: 10.20517/cdr.2021.59. eCollection 2021.
Abstract
摘要
相似文献
1
Tackling cisplatin resistance in ovarian cancer: what can we do?应对卵巢癌中的顺铂耐药性：我们能做些什么？
Cancer Drug Resist. 2021 Jul 8;4(4):755-757. doi: 10.20517/cdr.2021.59. eCollection 2021.
2
cRGD-targeted heparin nanoparticles for effective dual drug treatment of cisplatin-resistant ovarian cancer.载 cRGD 靶向肝素纳米粒的双重载药系统用于顺铂耐药卵巢癌细胞的有效治疗
J Control Release. 2023 Apr;356:691-701. doi: 10.1016/j.jconrel.2023.03.017. Epub 2023 Mar 23.
3
FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway.FAM83B通过抑制Wnt信号通路来抑制卵巢癌顺铂耐药。
Oncogenesis. 2021 Jan 9;10(1):6. doi: 10.1038/s41389-020-00301-y.
4
Role of autophagy in cisplatin resistance in ovarian cancer cells.自噬在卵巢癌细胞顺铂耐药中的作用。
J Biol Chem. 2014 Jun 13;289(24):17163-73. doi: 10.1074/jbc.M114.558288. Epub 2014 May 2.
5
[The mechanism of cisplatin-resistance in ovarian cancer].[卵巢癌顺铂耐药的机制]
Hum Cell. 2001 Jun;14(2):115-33.
6
STAT3 regulated promotes ovarian cancer proliferation and cisplatin resistance.STAT3 调控促进卵巢癌细胞增殖和顺铂耐药性。
Biosci Rep. 2018 Aug 29;38(4). doi: 10.1042/BSR20180547. Print 2018 Aug 31.
7
LNC00115 Mediates Cisplatin Resistance by Regulating the miR-7/ERK Signalling Pathway in Ovarian Cancer.LNC00115通过调控卵巢癌中的miR-7/ERK信号通路介导顺铂耐药。
Cancer Manag Res. 2021 May 11;13:3817-3826. doi: 10.2147/CMAR.S295097. eCollection 2021.
8
DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.DUOXA1 介导的活性氧产生通过激活 ATR-Chk1 通路促进卵巢癌对顺铂的耐药性。
Cancer Lett. 2018 Aug 1;428:104-116. doi: 10.1016/j.canlet.2018.04.029. Epub 2018 Apr 26.
9
Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer.OGT 的下调通过诱导卵巢癌细胞自噬促进顺铂耐药。
Theranostics. 2018 Oct 6;8(19):5200-5212. doi: 10.7150/thno.27806. eCollection 2018.
10
Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.miR-503的下调通过靶向PI3K p85促进卵巢癌耐药性的发展。
Arch Gynecol Obstet. 2018 Mar;297(3):699-707. doi: 10.1007/s00404-018-4649-0. Epub 2018 Jan 11.
引用本文的文献
1
Non-coding RNA and drug resistance in head and neck cancer.非编码RNA与头颈癌中的耐药性
Cancer Drug Resist. 2024 Sep 20;7:34. doi: 10.20517/cdr.2024.59. eCollection 2024.
2
Emerging role of MYB transcription factors in cancer drug resistance.MYB转录因子在癌症耐药性中的新作用。
Cancer Drug Resist. 2024 Apr 30;7:15. doi: 10.20517/cdr.2023.158. eCollection 2024.
本文引用的文献
1
Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer.靶向上皮性卵巢癌中的PI3K/AKT/mTOR信号通路，铂耐药卵巢癌的治疗选择
Cancer Drug Resist. 2021 Apr 14;4(3):573-595. doi: 10.20517/cdr.2021.05. eCollection 2021.
2
Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy.靶向雷帕霉素靶蛋白（mTOR）和真核翻译起始因子4E（eIF4E）：卵巢癌治疗中的一种可行方案。
Cancer Drug Resist. 2021 May 11;4(3):596-606. doi: 10.20517/cdr.2021.20. eCollection 2021.
3
How to win the ovarian cancer stem cell battle: destroying the roots.如何打赢卵巢癌干细胞之战：斩草除根。
Cancer Drug Resist. 2020 Dec 22;3(4):1021-1033. doi: 10.20517/cdr.2020.93. eCollection 2020.
4
History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications.卵巢癌腹腔内铂类药物递送的历史及其未来应用
Cancer Drug Resist. 2021 Jun 19;4(2):453-462. doi: 10.20517/cdr.2020.116. eCollection 2021.
5
The emerging roles of E3 ubiquitin ligases in ovarian cancer chemoresistance.E3泛素连接酶在卵巢癌化疗耐药中的新作用
Cancer Drug Resist. 2021 Jun 19;4(2):365-381. doi: 10.20517/cdr.2020.115. eCollection 2021.
Zotero 插件